Literature DB >> 9306599

Secondary hyperparathyroidism: pathophysiology, histopathology, and medical and surgical management.

Y Tominaga1, H Johansson, H Johansson, H Takagi.   

Abstract

It is generally accepted that morphological changes of the parathyroid glands appear early in renal failure. When diffuse hyperplasia develops into a nodular type, the cells grow monoclonally and proliferate aggressively, with abnormal suppression of parathyroid hormone (PTH) secretion under high extracellular calcium. Based on histopathological and pathophysiological findings, patients with nodular hyperplasia in renal hyperparathyroidism might be refractory to medical treatment, including calcitriol pulse therapy. Thus, parathyroid surgery is indicated for individuals developing hypercalcemia, elevated PTH levels, and/or bone disease, who cannot be effectively treated medically. The detection of enlarged parathyroid glands by image diagnosis is another criterion for surgery. In our experience, parathyroidectomy is an effective treatment; however, the timing of the operation is important, because skeletal deformity and vessel calcification cannot be expected to diminish even after successful surgery. Technically, it is important to identify all parathyroid glands and, in autotransplantation, to use an adequate amount of suitable tissue, namely, a diffuse type of hyperplastic tissue, to guarantee satisfactory postoperative function.

Entities:  

Mesh:

Year:  1997        PMID: 9306599     DOI: 10.1007/BF02385267

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.540


  37 in total

1.  Regulation of parathyroid cell gene expression in experimental uremia.

Authors:  Y Shvil; T Naveh-Many; P Barach; J Silver
Journal:  J Am Soc Nephrol       Date:  1990-07       Impact factor: 10.121

2.  Inhibition of cell growth retains differentiated function of bovine parathyroid cells in monolayer culture.

Authors:  P Nygren; R Larsson; H Johansson; E Gylfe; J Rastad; G Akerström
Journal:  Bone Miner       Date:  1988-06

3.  Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.

Authors:  M Fukagawa; M Kitaoka; H Yi; N Fukuda; T Matsumoto; E Ogata; K Kurokawa
Journal:  Nephron       Date:  1994       Impact factor: 2.847

4.  Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure.

Authors:  A B Korkor
Journal:  N Engl J Med       Date:  1987-06-18       Impact factor: 91.245

5.  Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

Authors:  E Slatopolsky; C Weerts; J Thielan; R Horst; H Harter; K J Martin
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

6.  Extrarenal production of calcitriol in normal and uremic humans.

Authors:  A S Dusso; J Finch; A Brown; C Ritter; J Delmez; G Schreiner; E Slatopolsky
Journal:  J Clin Endocrinol Metab       Date:  1991-01       Impact factor: 5.958

7.  Microfluorometric measurements of cytoplasmic calcium in chief and oxyphil parathyroid cells of adenomatous and hyperplastic glands and of normal-sized glands associated with adenomas.

Authors:  H Johansson; J Rastad; G Bjerneroth; E Gylfe; G Akerström
Journal:  Surgery       Date:  1989-09       Impact factor: 3.982

8.  1,25(OH)2D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells.

Authors:  P Nygren; R Larsson; H Johansson; S Ljunghall; J Rastad; G Akerström
Journal:  Calcif Tissue Int       Date:  1988-10       Impact factor: 4.333

9.  Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure.

Authors:  Y Tominaga; K Sato; Y Tanaka; M Numano; K Uchida; H Takagi
Journal:  Clin Nephrol       Date:  1995-11       Impact factor: 0.975

10.  Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.

Authors:  T Naveh-Many; R Rahamimov; N Livni; J Silver
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  5 in total

1.  Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation.

Authors:  Emad Kandil; Sandy Florman; Haythem Alabbas; Obai Abdullah; Jennifer McGee; Salem Noureldine; Douglas Slakey; Rubin Zhang
Journal:  Am J Med Sci       Date:  2010-05       Impact factor: 2.378

2.  Tumoral calcinosis revisited: pathophysiology and treatment.

Authors:  Gregor Möckel; Frank Buttgereit; Karsten Labs; Carsten Perka
Journal:  Rheumatol Int       Date:  2003-09-12       Impact factor: 2.631

3.  Total parathyroidectomy and autotransplantation by the subcutaneous injection technique in secondary hyperparathyroidism.

Authors:  Jong Ho Yoon; Kee-Hyun Nam; Hang-Seok Chang; Woong Youn Chung; Cheong Soo Park
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

4.  Assessing the site of recurrence in patients with secondary hyperparathyroidism by a simplified Casanova autograftectomy test.

Authors:  Katja Schlosser; Helmut Sitter; Matthias Rothmund; Andreas Zielke
Journal:  World J Surg       Date:  2004-06       Impact factor: 3.352

5.  Increase in bone mineral density after successful parathyroidectomy for tertiary hyperparathyroidism after renal transplantation.

Authors:  Stéphane Collaud; Tania Staub-Zähner; Andrea Trombetti; Thomas Clerici; Nicola Marangon; Isabelle Binet; Patrick O Myers; René Rizzoli; Pierre-Yves Martin; John H Robert; Frederic Triponez
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.